Insights

Innovative Oncology Focus invIOs specializes in developing novel immuno-oncology therapeutics targeting solid tumors, presenting opportunities to collaborate with biotech and pharmaceutical companies seeking advanced cancer treatments.

Strategic Collaborations The company's partnerships with prestigious institutes like Dana-Farber highlight its collaborative approach, opening avenues to offer joint development projects, licensing, or co-marketing deals within the cancer therapeutics space.

Funding and Growth Potential Having secured nearly $9 million in Series A funding and being in early stages of development, invIOs offers prospects for early investor engagement, strategic partnerships, or technology licensing to accelerate pipeline progression.

Pipeline Advancements invIOs’s focus on preclinical and clinical trial progression for its assets like INV501 creates opportunities for CROs, research organizations, or equipment providers to support its development efforts.

Market Entry Opportunities With a recent Scientific Advisory Board launch and active research collaborations, there are potential avenues for service providers in scientific consulting, clinical trial support, or biotech commercialization services to engage with the company’s growth initiatives.

invIOs INNOVATIVE IMMUNO-ONCOLOGY Tech Stack

invIOs INNOVATIVE IMMUNO-ONCOLOGY uses 8 technology products and services including Cloudflare, oEmbed, Slider Revolution, and more. Explore invIOs INNOVATIVE IMMUNO-ONCOLOGY's tech stack below.

Cloudflare

Content Management System

oEmbed

Dev Tools

Slider Revolution

Miscellaneous

PHP

Programming Languages

Yoast SEO

Search Engines

SVG Support

Web Platform Extensions

Apache

Web Servers

TouchSwipe

Web Tools And Plugins

invIOs INNOVATIVE IMMUNO-ONCOLOGY Email Formats	Example	Percentage
First.Last@apeiron-biologics.com	John.Doe@apeiron-biologics.com	100%
L.First@invios.com	D.John@invios.com	50%
Last.First@invios.com	Doe.John@invios.com	50%

invIOs INNOVATIVE IMMUNO-ONCOLOGY Email Formats

Example

Percentage

First.Last@apeiron-biologics.com

John.Doe@apeiron-biologics.com

100%

L.First@invios.com

D.John@invios.com

50%

Last.First@invios.com

Doe.John@invios.com

50%

Frequently Asked Questions

Where is invIOs INNOVATIVE IMMUNO-ONCOLOGY's headquarters located?

invIOs INNOVATIVE IMMUNO-ONCOLOGY's main headquarters is located at 5 Campus-vienna-biocenter Vienna, Wien 1030 Austria. The company has employees across 2 continents, including EuropeNorth America.

What is invIOs INNOVATIVE IMMUNO-ONCOLOGY's official website and social media links?

invIOs INNOVATIVE IMMUNO-ONCOLOGY's official website is invios.com and has social profiles on LinkedIn Crunchbase.

What is invIOs INNOVATIVE IMMUNO-ONCOLOGY's SIC code NAICS code?

invIOs INNOVATIVE IMMUNO-ONCOLOGY's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does invIOs INNOVATIVE IMMUNO-ONCOLOGY have currently?

As of February 2026, invIOs INNOVATIVE IMMUNO-ONCOLOGY has approximately 15 employees across 2 continents, including EuropeNorth America. Key team members include Head Of It: A. N.Cmso: R. G.: M. M.. Explore invIOs INNOVATIVE IMMUNO-ONCOLOGY's employee directory with LeadIQ.

What industry does invIOs INNOVATIVE IMMUNO-ONCOLOGY belong to?

invIOs INNOVATIVE IMMUNO-ONCOLOGY operates in the Biotechnology Research industry.

What technology does invIOs INNOVATIVE IMMUNO-ONCOLOGY use?

invIOs INNOVATIVE IMMUNO-ONCOLOGY's tech stack includes CloudflareoEmbedSlider RevolutionPHPYoast SEOSVG SupportApacheTouchSwipe.

What is invIOs INNOVATIVE IMMUNO-ONCOLOGY's email format?

invIOs INNOVATIVE IMMUNO-ONCOLOGY's email format typically follows the pattern of First.Last@apeiron-biologics.com. Find more invIOs INNOVATIVE IMMUNO-ONCOLOGY email formats with LeadIQ.

How much funding has invIOs INNOVATIVE IMMUNO-ONCOLOGY raised to date?

As of February 2026, invIOs INNOVATIVE IMMUNO-ONCOLOGY has raised $8.9M in funding. The last funding round occurred on Oct 15, 2024 for $8.9M.

When was invIOs INNOVATIVE IMMUNO-ONCOLOGY founded?

invIOs INNOVATIVE IMMUNO-ONCOLOGY was founded in 2021.

invIOs INNOVATIVE IMMUNO-ONCOLOGY

Q: What technology does invIOs INNOVATIVE IMMUNO-ONCOLOGY use?

invIOs INNOVATIVE IMMUNO-ONCOLOGY's tech stack includes jQuery Migrate, Complianz, SVG Support, OWL Carousel, jQuery.

Biotechnology ResearchWien, Austria11-50 Employees

invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer.
We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials.
We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics.
Our highly motivated team of 35 people has deep expertise across the biotechnology value chain, with in-house expertise in R&D, clinical development, CMC, IP, scouting and more.
All of our approaches are designed with a single goal: To transform patients' lives, so that cancer doesn’t.

Insights

Similar companies to invIOs INNOVATIVE IMMUNO-ONCOLOGY

IO Biotech

Oxford BioTherapeutics

Celsius Therapeutics

Invectys

Kytopen

iTeos Therapeutics

ImCheck Therapeutics